An Open-label, Phase 3, Multicenter Study to Evaluate the Pharmacokinetics Following a Single Oral Dose of TAK-536 in Pediatric Patients 6 to Less Than 16 Years of Age With Hypertension
Phase of Trial: Phase III
Latest Information Update: 23 Aug 2016
At a glance
- Drugs Azilsartan (Primary)
- Indications Hypertension
- Focus Adverse reactions; Pharmacokinetics; Registrational
- Sponsors Takeda
- 07 Jan 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 19 Oct 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 09 Jul 2015 Planned initiation date changed from 1 Jun 2015 to 1 Jul 2015 as reported by ClinicalTrials.gov.